
Carlo Briguori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3403796/publications.pdf Version: 2024-02-01



CARLO RRICHORI

#	Article	IF	CITATIONS
1	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	13.9	683
2	Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). Circulation, 2007, 115, 1211-1217.	1.6	438
3	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	13.9	334
4	Management of Coronary Disease in Patients with Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1608-1618.	13.9	310
5	Novel Approaches for Preventing or Limiting Events (Naples) II Trial. Journal of the American College of Cardiology, 2009, 54, 2157-2163.	1.2	223
6	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II). Circulation, 2011, 124, 1260-1269.	1.6	217
7	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
8	Cystatin C and Contrast-Induced Acute Kidney Injury. Circulation, 2010, 121, 2117-2122.	1.6	212
9	ls Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	1.1	135
10	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122
11	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	1.0	93
12	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB Journal, 2010, 24, 1981-1988.	0.2	80
13	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	1.2	60
14	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	1.0	54
15	Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry. EuroIntervention, 2020, 15, e1343-e1350.	1.4	51
16	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1166-1175.	1.1	49
17	Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI. International Journal of Cardiology, 2019, 293, 84-90.	0.8	46
18	Novel Approaches for Preventing or LimitingÂEvents (Naples) III Trial. JACC: Cardiovascular Interventions, 2015, 8, 414-423.	1.1	45

CARLO BRIGUORI

#	Article	IF	CITATIONS
19	Nephrotoxicity of contrast media and protective effects of acetylcysteine. Archives of Toxicology, 2011, 85, 165-173.	1.9	41
20	Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial. Circulation: Cardiovascular Interventions, 2011, 4, 121-129.	1.4	41
21	Novel Biomarkers for Contrast-Induced Acute Kidney Injury. BioMed Research International, 2014, 2014, 1-5.	0.9	41
22	RenalGuard system in high-risk patients for contrast-induced acute kidney injury. American Heart Journal, 2016, 173, 67-76.	1.2	39
23	Neutrophil Gelatinase–Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2015, 8, e002673.	1.4	38
24	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	0.8	33
25	Bivalirudin or Heparin in Patients Undergoing Invasive Management of AcuteÂCoronaryÂSyndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	1.2	32
26	Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release. European Heart Journal, 2021, 42, 2780-2792.	1.0	32
27	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	1.4	30
28	Left Ventricular End-Diastolic Pressure Versus Urine Flow Rate–Guided Hydration in Preventing Contrast-Associated Acute Kidney Injury. JACC: Cardiovascular Interventions, 2020, 13, 2065-2074.	1.1	29
29	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	1.1	27
30	RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 11, e1658-e1661.	1.4	27
31	One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	0.8	25
32	Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Internal Carotid Artery Stent Implantation. JACC: Cardiovascular Interventions, 2015, 8, 1506-1514.	1.1	24
33	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation, 2021, 144, 1380-1395.	1.6	24
34	Contrast-induced acute kidney injury. Current Opinion in Nephrology and Hypertension, 2015, 24, 145-153.	1.0	23
35	Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention, 2011, 6, 1117-1122.	1.4	22
36	The STENTYS® paclitaxelâ€eluting stent in the treatment of unprotected distal left main. Catheterization and Cardiovascular Interventions, 2015, 86, E131-9.	0.7	21

CARLO BRIGUORI

#	Article	IF	CITATIONS
37	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. Journal of the American College of Cardiology, 2021, 77, 2667-2676.	1.2	18
38	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	1.0	18
39	Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 999-1006.	0.4	16
40	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). International Journal of Cardiology, 2018, 260, 36-41.	0.8	15
41	Hydration in contrast-induced acute kidney injury. Lancet, The, 2014, 383, 1786-1788.	6.3	13
42	Impact of a contrast media volume control device on acute kidney injury rate in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2021, 98, 76-84.	0.7	13
43	Safety and feasibility of balloon aortic valvuloplasty in nonâ€₹AVI centers: The "BAV for life―experience. Catheterization and Cardiovascular Interventions, 2019, 93, E63-E70.	0.7	12
44	Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE) Tj ETQq0 0	0ogBT /O	venbock 10 T
45	Biomarkers of Contrast-Induced Nephropathy:. Interventional Cardiology Clinics, 2020, 9, 335-344.	0.2	12
46	Recalcitrant inâ€stent restenosis of the celiac trunk treated by drugâ€eluting stent. Catheterization and Cardiovascular Interventions, 2008, 72, 873-876.	0.7	11
47	Renalguard system: A dedicated device to prevent contrast-induced acute kidney injury. International Journal of Cardiology, 2013, 168, 643-644.	0.8	11
48	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer) Tj ETQq0 0 0 r	g &T.\$ Over	o ak 10 Tf 50
49	Clinical outcomes with reservoirâ€based polymerâ€free amphilimusâ€eluting stents in realâ€world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. Catheterization and Cardiovascular Interventions, 2018, 91, 884-891.	0.7	11
50	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 533-541.	0.7	11
51	Tailored Versus Standard Hydration to Prevent Acute Kidney Injury After Percutaneous Coronary Intervention: Network Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e021342.	1.6	11
52	Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Throught The Femoral Approach. Rationale and Design. Cardiovascular Drugs and Therapy, 2014, 28, 273-279.	1.3	10
53	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. International Journal of Cardiology, 2017, 244, 112-118.	0.8	10
54	Renal insufficiency following contrast media administration trial III: Urine flow rateâ€guided versus leftâ€ventricular endâ€diastolic pressureâ€guided hydration in highâ€risk patients for contrastâ€induced acute kidney injury. Rationale and design. Catheterization and Cardiovascular Interventions, 2020, 95, 895-903.	0.7	10

CARLO BRIGUORI

#	Article	IF	CITATIONS
55	The CID Chronoâ,"¢ cobalt–chromium alloy carbofilm-coated coronary stent system. International Journal of Cardiology, 2011, 149, 199-204.	0.8	9
56	Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension, 2011, 2011, 1-12.	0.5	9
57	Persistent serum creatinine increase following contrastâ€induced acute kidney injury. Catheterization and Cardiovascular Interventions, 2018, 91, 1185-1191.	0.7	9
58	The impact of the extent of side branch disease on outcomes following bifurcation stenting. Catheterization and Cardiovascular Interventions, 2020, 96, E84-E92.	0.7	8
59	In Vivo Histological Assessment of a Spontaneous Coronary Artery Dissection. Circulation, 2010, 122, 1044-1046.	1.6	7
60	Endothelial progenitor cells in coronary artery disease. Biological Chemistry, 2013, 394, 1241-1252.	1.2	7
61	Coronary artery bifurcation narrowing treated by Axxess stent implantation: The CARINAX registry. Catheterization and Cardiovascular Interventions, 2017, 89, E112-E123.	0.7	7
62	Oneâ€Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimusâ€Eluting Stents in High Bleeding Risk Patients. Journal of the American Heart Association, 2022, 11, e023454.	1.6	7
63	The glider balloon: A useful device for the treatment of bifurcation lesions. International Journal of Cardiology, 2013, 168, 3208-3211.	0.8	6
64	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. Catheterization and Cardiovascular Interventions, 2021, 97, 63-71.	0.7	6
65	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA KD. Journal of the American Heart Association, 2022, 11, e022003.	1.6	6
66	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 972-979.	0.7	5
67	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. European Heart Journal Cardiovascular Imaging, 2019, 20, 1418-1428.	0.5	5
68	Sirolimusâ€eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis. Catheterization and Cardiovascular Interventions, 2019, 94, 323-331.	0.7	5
69	Paclitexel versus sirolimus-coated balloon in the treatment of coronary instent restenosis. Panminerva Medica, 2023, 65, .	0.2	5
70	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	1.4	5
71	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	1.4	5
72	DyeVert Contrast Reduction System Use in Patients Undergoing Coronary and/or Peripheral Angiography: A Systematic Literature Review and Meta-Analysis. Frontiers in Medicine, 2022, 9, 841876.	1.2	5

#	Article	IF	CITATIONS
73	Prospective evaluation of drug eluting selfâ€apposing stent for the treatment of unprotected left main coronary artery disease: 1â€year results of the TRUNC study. Catheterization and Cardiovascular Interventions, 2020, 96, E142-E148.	0.7	4
74	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). Catheterization and Cardiovascular Interventions, 2020, 96, 255-265.	0.7	4
75	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting ProlongedÂBivalirudin Infusion. JACC: Cardiovascular Imaging, 2019, 12, 934-936.	2.3	3
76	Predictors of strut coverage of drug eluting stent implantation in diabetic patients. International Journal of Cardiology, 2019, 276, 61-65.	0.8	3
77	Preoperative evaluation of caseous calcification of the mitral annulus by TrueVue transillumination rendering. International Journal of Cardiovascular Imaging, 2020, 36, 1697-1698.	0.7	3
78	Elective Mechanical Circulatory Support in the Percutaneous Treatment of Patients With Combined Complex Coronary Artery Disease and Severe Aortic Valve Stenosis. Journal of Invasive Cardiology, 2019, 31, 52-56.	0.4	3
79	The Avantgarde Carbostent in Patients Scheduled for Undelayable Noncardiac Surgery. Thrombosis, 2012, 2012, 1-6.	1.4	2
80	Assessment of residual thrombus burden in patients with STâ€segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq0 0 0 rg	BT /Qverlo	ck ₂ 10 Tf 50 4
	Cardiovascular Interventions, 2020, 96, 1156-1171.		
81	Left ventricular support during complex transradial percutaneous coronary intervention for complete revascularization. Minerva Cardioangiologica, 2019, 67, 348-355.	1.2	2
82	Statins and contrast-induced acute kidney injury. Coronary Artery Disease, 2014, 25, 550-551.	0.3	1
83	Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment. Journal of Cardiovascular Medicine, 2018, 19, 564-570.	0.6	1
84	Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply. International Journal of Cardiology, 2019, 283, 95.	0.8	1
85	Stent thrombosis in patients with chronic kidney disease. Expert Review of Cardiovascular Therapy, 2012, 10, 617-626.	0.6	0
86	Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention. Cardiovascular Drugs and Therapy, 2015, 29, 105-106.	1.3	0
87	STENTYS coronary system: current status and future direction. Minerva Cardiology and Angiology, 2021, 69, 201-214.	0.4	0
88	Early P2Y ₁₂ Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin?. Circulation: Cardiovascular Interventions, 2021, 14, e010880.	1.4	0
89	The "locking and dragging―technique a facilitated crossover balloon occlusion technique for complex iliofemoral anatomy in transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, 98, E968-E970.	0.7	0
90	Nonpulsatile Systemic Flow During Mechanical Circulatory Support in Acute Myocardial Infarction–Related Cardiogenic Shock. , 2022, , 100384.		0